PCRX earnings call for the period ending June 30, 2019.
News & Analysis: Pacira BioSciences
Heron's pain is Pacira's gain.
The company's shares are rallying today on an analyst upgrade.
Despite a mixed third-quarter report, Pacira topped Wall Street's expectations where it counts.
Disappointing late-stage trial data is dashing investor optimism.
Fourth-quarter financials that were better than hoped are sparking interest in this drugmaker.
A better-than-hoped-for forecast for sales and profits fueled today's rally.
Better-than-expected sales and profits are igniting investor optimism.
One figure in Pacira's first-quarter earnings report is worrying Wall Street.